[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2005033048A3 - Wnt pathway antagonists - Google Patents

Wnt pathway antagonists Download PDF

Info

Publication number
WO2005033048A3
WO2005033048A3 PCT/US2004/032148 US2004032148W WO2005033048A3 WO 2005033048 A3 WO2005033048 A3 WO 2005033048A3 US 2004032148 W US2004032148 W US 2004032148W WO 2005033048 A3 WO2005033048 A3 WO 2005033048A3
Authority
WO
WIPO (PCT)
Prior art keywords
wnt pathway
pathway antagonists
compounds
pathologies
compositions
Prior art date
Application number
PCT/US2004/032148
Other languages
French (fr)
Other versions
WO2005033048A2 (en
Inventor
Philip A Beachy
James K Chen
Randall K Mann
Original Assignee
Univ Johns Hopkins
Philip A Beachy
James K Chen
Randall K Mann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Philip A Beachy, James K Chen, Randall K Mann filed Critical Univ Johns Hopkins
Priority to US10/574,248 priority Critical patent/US7652043B2/en
Publication of WO2005033048A2 publication Critical patent/WO2005033048A2/en
Publication of WO2005033048A3 publication Critical patent/WO2005033048A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/22—Naphthotriazoles
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Aromatic compounds for treating various diseases and pathologies are disclosed. The methods use of such compounds are also provided. Accordingly, the present invention makes available methods and compositions for inhibiting aberrant growth states in cells having Wnt receptors.
PCT/US2004/032148 2003-09-29 2004-09-29 Wnt pathway antagonists WO2005033048A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/574,248 US7652043B2 (en) 2004-09-29 2004-09-29 WNT pathway antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50716303P 2003-09-29 2003-09-29
US60/507,163 2003-09-29

Publications (2)

Publication Number Publication Date
WO2005033048A2 WO2005033048A2 (en) 2005-04-14
WO2005033048A3 true WO2005033048A3 (en) 2005-08-04

Family

ID=34421589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/032148 WO2005033048A2 (en) 2003-09-29 2004-09-29 Wnt pathway antagonists

Country Status (1)

Country Link
WO (1) WO2005033048A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105132357A (en) * 2015-07-29 2015-12-09 赫柏慧康生物科技无锡有限公司 Serum-free culture system for epidermal cell culture

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563813B2 (en) * 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
WO2007030658A2 (en) 2005-09-08 2007-03-15 Children's Hospital Medical Center Compositions useful for and methods of modulating angiogenesis
WO2008021250A2 (en) * 2006-08-10 2008-02-21 Fred Hutchinson Cancer Research Center Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
CL2007003223A1 (en) * 2006-11-10 2008-01-11 Wyeth Corp Compounds derived from n-substituted piperidinyl 4-arylsulfonamides, which act as modulators of the sfrp-1 protein; process to prepare the compounds; pharmaceutical composition comprising said co-compounds and use of the compounds to prepare medicaments for the treatment of diseases.
EP2148865B1 (en) * 2007-04-30 2017-05-17 Genentech, Inc. Pyrazole inhibitors of wnt signaling
HUE034563T2 (en) 2007-08-10 2018-02-28 Vm Discovery Inc Compositions and methods for apoptosis modulators
CA2911990C (en) * 2007-09-10 2018-03-20 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
WO2011041737A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Gain-of-function bcl-2 inhibitors
WO2011041731A2 (en) 2009-10-02 2011-04-07 Fred Hutchinson Cancer Research Center Method of inhibiting bcl-2-related survival proteins
CN103025159A (en) 2010-03-19 2013-04-03 波士顿生物医学公司 Novel methods for targeting cancer stem cells
BR112015025347A2 (en) 2013-04-09 2017-07-18 Boston Biomedical Inc 2-acetyl naphtho [2-3-b] furan-4,9-dione for use in cancer treatment
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CA2987289A1 (en) 2015-06-11 2016-12-15 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4378360A (en) * 1980-04-22 1983-03-29 Beecham Group Limited 6-{3-[4-(Substituted benzyl)-1-piperazinyl]propyloxy}-4,9-dihydro-4,9-dioxo-1H-naphtho[2,3-d-]-v
US4424361A (en) * 1980-01-23 1984-01-03 Beecham Group Limited Process for preparing polycyclic triazoles used to inhibit allergic responses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424361A (en) * 1980-01-23 1984-01-03 Beecham Group Limited Process for preparing polycyclic triazoles used to inhibit allergic responses
US4378360A (en) * 1980-04-22 1983-03-29 Beecham Group Limited 6-{3-[4-(Substituted benzyl)-1-piperazinyl]propyloxy}-4,9-dihydro-4,9-dioxo-1H-naphtho[2,3-d-]-v

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105132357A (en) * 2015-07-29 2015-12-09 赫柏慧康生物科技无锡有限公司 Serum-free culture system for epidermal cell culture

Also Published As

Publication number Publication date
WO2005033048A2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
WO2005033048A3 (en) Wnt pathway antagonists
WO2005033288A3 (en) Hedgehog pathway antagonists
WO2006021881A3 (en) Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
WO2006021884A3 (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
AP2006003525A0 (en) Ä1,8ÜNapthyridin-2-ones and related compounds for the treatment of schizophrenia.
WO2007079164A3 (en) Protein kinase inhibitors
NL1025071A1 (en) Compounds for the treatment of abnormal cell growth.
EP1638508A4 (en) Shunt for the treatment of glaucoma
EP1583821A4 (en) Methods and compositions for treating urological disorders using 44390, 54181, 211, 5687, 884, 1405, 636, 4421, 5410, 30905, 2045, 16405, 18560, 2047, 33751, 52872, 14063, 20739, 32544, 43239, 44373, 51164, 53010, 16852, 1587, 2207, 22245, 2387, 52908, 69112, 14990, 18547, 115, 579, 15985, 15625, 76
IL178419A0 (en) 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
WO2006073939A3 (en) 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
WO2006050109A3 (en) Novel kinase inhibitors
WO2005046603A3 (en) Pyridine compounds
IL175992A0 (en) Substituted arylpyrazoles as parasiticidal agents
WO2004009062A3 (en) NMDA RECEPTOR ANTAGONISTS AND THEIR USE IN INHIBITING ABNORMAL HYPERPHOSPHORYLATION OF MICROTUBULE ASSOCIATED PROTEIN tau
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
JO2578B1 (en) 228 Benzimidazole Thiophene Compounds
WO2005091853A3 (en) Methods and compositions for treating il-13 related pathologies
HUE037069T2 (en) Process for the preparation of highly pure 2,4'-methylenediphenyldiisocyanate
HK1103631A1 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
AU2003201817A1 (en) Telomere-encoding synthetic dna nanocircles, and their use for the elongation of telomere repeats
WO2004043379A3 (en) Chemical compounds
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
WO2004087066A3 (en) Hif-1 inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 10574248

Country of ref document: US

Ref document number: 2007219257

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10574248

Country of ref document: US